Kaiser, Jacqueline
Nay, Kevin
Horne, Christopher R.
McAloon, Luke M.
Fuller, Oliver K. https://orcid.org/0000-0003-1914-922X
Muller, Abbey G. https://orcid.org/0000-0002-6455-9124
Whyte, Douglas G. https://orcid.org/0000-0001-9232-7198
Means, Anthony R.
Walder, Ken
Berk, Michael
Hannan, Anthony J. https://orcid.org/0000-0001-7532-8922
Murphy, James M. https://orcid.org/0000-0003-0195-3949
Febbraio, Mark A.
Gundlach, Andrew L.
Scott, John W. https://orcid.org/0000-0002-1896-9798
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (2001817, 1156072, 2017131, 1172929, 9000719, 1116936, 1194141, 2001817)
Article History
Received: 20 December 2022
Revised: 30 August 2023
Accepted: 8 September 2023
First Online: 20 September 2023
Competing interests
: MAF is a founder and shareholder of Celesta Therapeutics. All other authors declare no conflict of interest.